Use of serial FDG pet to measure the response of bone-dominant breast cancer to therapy

Stephanie E. Stafford, Julie R. Gralow, Erin K. Schubert, Kristine J. Rinn, Lisa K. Dunnwald, Robert B Livingston, David A. Mankoff

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Rationale and Objectives. The authors performed this study to determine the feasibility of using quantitative 2-[fluorine- 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to monitor the response of breast cancer bone metastases to therapy. Materials and Methods. Twenty-four women with stage IV bone-dominant breast carcinoma were included in this study. Whole-body FDG PET imaging was performed at serial time points during the course of therapy. FDG PET scans were interpreted quantitatively by using the maximum standard uptake value (SUV) of the most conspicuous bone lesion at baseline FDG PET. PET results were compared to the overall assessment of response (response, stable disease, progressive disease) with a combination of conventional imaging, change in tumor marker values, and subjective symptom changes by experienced medical oncologists blinded to the findings at FDG PET. Changes in FDG SUV were also correlated quantitatively to the changes in a particular tumor marker (CA 27.29). Results. The changes in FDG SUV with therapy showed correlation with the overall clinical assessment of response (P < .01). The percentage change in FDG uptake with therapy showed strong correlation with the percentage change in tumor marker value (P < .01). Conclusion. Preliminary results indicate that serial whole-body FDG PET can help quantitatively assess the response of breast cancer bone metastases to therapy. Prospective trials are needed to further investigate its accuracy.

Original languageEnglish (US)
Pages (from-to)913-921
Number of pages9
JournalAcademic Radiology
Volume9
Issue number8
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Pets
Deoxyglucose
Positron-Emission Tomography
Breast Neoplasms
Bone and Bones
Tumor Biomarkers
Bone Neoplasms
Therapeutics
Neoplasm Metastasis
Fluorine

Keywords

  • Breast neoplasms, diagnostic radiology
  • Breast neoplasms, emission CT
  • Breast neoplasms, metastases
  • Imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Stafford, S. E., Gralow, J. R., Schubert, E. K., Rinn, K. J., Dunnwald, L. K., Livingston, R. B., & Mankoff, D. A. (2002). Use of serial FDG pet to measure the response of bone-dominant breast cancer to therapy. Academic Radiology, 9(8), 913-921. https://doi.org/10.1016/S1076-6332(03)80461-0

Use of serial FDG pet to measure the response of bone-dominant breast cancer to therapy. / Stafford, Stephanie E.; Gralow, Julie R.; Schubert, Erin K.; Rinn, Kristine J.; Dunnwald, Lisa K.; Livingston, Robert B; Mankoff, David A.

In: Academic Radiology, Vol. 9, No. 8, 2002, p. 913-921.

Research output: Contribution to journalArticle

Stafford, SE, Gralow, JR, Schubert, EK, Rinn, KJ, Dunnwald, LK, Livingston, RB & Mankoff, DA 2002, 'Use of serial FDG pet to measure the response of bone-dominant breast cancer to therapy', Academic Radiology, vol. 9, no. 8, pp. 913-921. https://doi.org/10.1016/S1076-6332(03)80461-0
Stafford, Stephanie E. ; Gralow, Julie R. ; Schubert, Erin K. ; Rinn, Kristine J. ; Dunnwald, Lisa K. ; Livingston, Robert B ; Mankoff, David A. / Use of serial FDG pet to measure the response of bone-dominant breast cancer to therapy. In: Academic Radiology. 2002 ; Vol. 9, No. 8. pp. 913-921.
@article{e48fec5680694ab8a1e85c77dcac4c78,
title = "Use of serial FDG pet to measure the response of bone-dominant breast cancer to therapy",
abstract = "Rationale and Objectives. The authors performed this study to determine the feasibility of using quantitative 2-[fluorine- 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to monitor the response of breast cancer bone metastases to therapy. Materials and Methods. Twenty-four women with stage IV bone-dominant breast carcinoma were included in this study. Whole-body FDG PET imaging was performed at serial time points during the course of therapy. FDG PET scans were interpreted quantitatively by using the maximum standard uptake value (SUV) of the most conspicuous bone lesion at baseline FDG PET. PET results were compared to the overall assessment of response (response, stable disease, progressive disease) with a combination of conventional imaging, change in tumor marker values, and subjective symptom changes by experienced medical oncologists blinded to the findings at FDG PET. Changes in FDG SUV were also correlated quantitatively to the changes in a particular tumor marker (CA 27.29). Results. The changes in FDG SUV with therapy showed correlation with the overall clinical assessment of response (P < .01). The percentage change in FDG uptake with therapy showed strong correlation with the percentage change in tumor marker value (P < .01). Conclusion. Preliminary results indicate that serial whole-body FDG PET can help quantitatively assess the response of breast cancer bone metastases to therapy. Prospective trials are needed to further investigate its accuracy.",
keywords = "Breast neoplasms, diagnostic radiology, Breast neoplasms, emission CT, Breast neoplasms, metastases, Imaging",
author = "Stafford, {Stephanie E.} and Gralow, {Julie R.} and Schubert, {Erin K.} and Rinn, {Kristine J.} and Dunnwald, {Lisa K.} and Livingston, {Robert B} and Mankoff, {David A.}",
year = "2002",
doi = "10.1016/S1076-6332(03)80461-0",
language = "English (US)",
volume = "9",
pages = "913--921",
journal = "Academic Radiology",
issn = "1076-6332",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Use of serial FDG pet to measure the response of bone-dominant breast cancer to therapy

AU - Stafford, Stephanie E.

AU - Gralow, Julie R.

AU - Schubert, Erin K.

AU - Rinn, Kristine J.

AU - Dunnwald, Lisa K.

AU - Livingston, Robert B

AU - Mankoff, David A.

PY - 2002

Y1 - 2002

N2 - Rationale and Objectives. The authors performed this study to determine the feasibility of using quantitative 2-[fluorine- 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to monitor the response of breast cancer bone metastases to therapy. Materials and Methods. Twenty-four women with stage IV bone-dominant breast carcinoma were included in this study. Whole-body FDG PET imaging was performed at serial time points during the course of therapy. FDG PET scans were interpreted quantitatively by using the maximum standard uptake value (SUV) of the most conspicuous bone lesion at baseline FDG PET. PET results were compared to the overall assessment of response (response, stable disease, progressive disease) with a combination of conventional imaging, change in tumor marker values, and subjective symptom changes by experienced medical oncologists blinded to the findings at FDG PET. Changes in FDG SUV were also correlated quantitatively to the changes in a particular tumor marker (CA 27.29). Results. The changes in FDG SUV with therapy showed correlation with the overall clinical assessment of response (P < .01). The percentage change in FDG uptake with therapy showed strong correlation with the percentage change in tumor marker value (P < .01). Conclusion. Preliminary results indicate that serial whole-body FDG PET can help quantitatively assess the response of breast cancer bone metastases to therapy. Prospective trials are needed to further investigate its accuracy.

AB - Rationale and Objectives. The authors performed this study to determine the feasibility of using quantitative 2-[fluorine- 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to monitor the response of breast cancer bone metastases to therapy. Materials and Methods. Twenty-four women with stage IV bone-dominant breast carcinoma were included in this study. Whole-body FDG PET imaging was performed at serial time points during the course of therapy. FDG PET scans were interpreted quantitatively by using the maximum standard uptake value (SUV) of the most conspicuous bone lesion at baseline FDG PET. PET results were compared to the overall assessment of response (response, stable disease, progressive disease) with a combination of conventional imaging, change in tumor marker values, and subjective symptom changes by experienced medical oncologists blinded to the findings at FDG PET. Changes in FDG SUV were also correlated quantitatively to the changes in a particular tumor marker (CA 27.29). Results. The changes in FDG SUV with therapy showed correlation with the overall clinical assessment of response (P < .01). The percentage change in FDG uptake with therapy showed strong correlation with the percentage change in tumor marker value (P < .01). Conclusion. Preliminary results indicate that serial whole-body FDG PET can help quantitatively assess the response of breast cancer bone metastases to therapy. Prospective trials are needed to further investigate its accuracy.

KW - Breast neoplasms, diagnostic radiology

KW - Breast neoplasms, emission CT

KW - Breast neoplasms, metastases

KW - Imaging

UR - http://www.scopus.com/inward/record.url?scp=0035991797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035991797&partnerID=8YFLogxK

U2 - 10.1016/S1076-6332(03)80461-0

DO - 10.1016/S1076-6332(03)80461-0

M3 - Article

C2 - 12186440

AN - SCOPUS:0035991797

VL - 9

SP - 913

EP - 921

JO - Academic Radiology

JF - Academic Radiology

SN - 1076-6332

IS - 8

ER -